3rd Annual Pharmaceutical Marketing and Sales Global Summit
The meeting carefully examines the changing marketing and sales models, posits strategic solutions for finding new opportunities in a fragmented market, how to implement new legislation, and addresses what executive marketing and sales executive management can do to thrive in the new environment.
Time for Pharma to Revamp Its Physician Marketing Strategy
Should pharma companies revamp their physician marketing strategies? Some idea of pharma's thinking on this topic is revealed in the emerging story of Pfizer's...
Pharma Sales Force Bloat and the Mythical Man-Month
A myth long believed at pharma companies --as well as at other companies -- is that by by hiring more salespeople you can proportionately...
Pfizer to Slash 30% of its Sales & Marketing Staff
Pfizer Inc. may slash its 38,000-member sales and marketing staff by as much as 30%, or 11,400 employees.
Pfizer Inc., the world's biggest drugmaker, may...
CBI’s Summit on Post-Marketing Studies
Featured Conference CBI's Summit on Post-Marketing Studies February 7 - 8, 2005 ...
It’s the land of success!
Big Pharma had a plan.
It designed a trial for a COX-2 drug and it ran.
Yet it wasn’t enough to get pain low.
What's this?
We’re still...
Times They Are A-Changing?
Now that market forces are starting to turn negative, have we reached a point where the bloat (inefficiency) is unsustainable? Or are threats of layoffs just a ploy to sustain stock market value?
Does the FDA Need to be Overhauled?
In the wake of the VIOXX withdrawal, critics have suggested that FDA needs to reform how it regulates the drug industry. Many suggestions for reform have been suggested.
Does the FDA Need to be Overhauled?
Does the FDA Need to be Overhauled? By John Mack (Bio) SUMMARY The Vioxx withdrawal put...
Numbers, Math and Communicating Risk
This article examines the numbers from Vioxx trials to illustrate how difficult it may be to communicate risk and benefit to consumers.
